The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.
Back Pain
About this trial
This is an interventional treatment trial for Back Pain focused on measuring chronic back pain, opioid, transdermal
Eligibility Criteria
Inclusion Criteria: unacceptable pain control despite currently taking a nonsteroidal anti-inflammatory drug considered at a therapeutic and/or tolerated dose or currently taking </=2 short-acting opioid doses per day. taking >/=3 opioid doses per day with or without acceptable pain control. Exclusion Criteria: receiving opioids at an average daily dose of greater than 60 mg of oral morphine equivalents or subjects receiving more than 6 tablets per day of a short-acting opioid. scheduled to have surgery (including dental) involving the use of post- or preoperative analgesics or anesthetics during the study period. Other protocol-specific exclusion/inclusion criteria may apply.
Sites / Locations
- Hawthorne & York, Intl, Ltd
- Arizona Research & Education
- Gainesville Clinical Research Center
- Park Place Therapeutic Center
- Atlanta Research Center
- Rheumatology Associates, Inc.
- Westside Family Medical Center
- The Center for Pharmaceutical Research
- The New York Hospital Cornell Medical Center
- NC Clinical Research, Inc.
- Pain Control Ctr Bowman Gray School of Med
- Metroplex Clinical Research Center